A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 1, 2003, Pages 155-161

  Ewbank, Penelope A ^a   Murray, Jacquelyn ^a   Sanders, Karrie ^a   Curran Everett, Douglas ^a,b   Dreskin, Stephen ^b   Nelson, Harold S ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cat extract; Cluster; Dose response; Immunologic response; Immunotherapy

Indexed keywords

ALLERGEN; CAT DANDER EXTRACT; FEL D 1; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; CAT; CELL SUBPOPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DANDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MAINTENANCE DRUG DOSE; MALE; MONONUCLEAR CELL; NOSE PROVOCATION TEST; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037253412     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.41     Document Type: Article

References (30)

1. Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000;106:41-5.
2. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967;201:915-7.
3. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993;91:709-22.
4. Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
5. Majchel AM, Proud D, Friedhoff L, Creticos PS, Norman PS, Naclerio RM. The nasal response to histamine challenge: effect of the pollen season and immunotherapy. J Allergy Clin Immunol 1992;90:85-91.
6. Creticos PS, Marsh DG, Proud D, Kagey-Sobotka A, Adkinson NF Jr, Friedhoff L, et al. Responses to ragweed pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 1989;84:197-205.
7. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk/benefit effects from a double-blind placebo study. 1994;93:556-66.
8. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, Kagey-Sobotka A, Khattignavong A, Norman PS Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988;82:1055-68.
9. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997;27:860-7.
10. Hedlin G, Graff-Lonnevig V, Heilborn H, Lilja G, Norrlind K, Pegelow K, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87:955-64.
11. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling H-J. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:1207-13.
12. Bousquet J, Lebel B, Khivert H, Bataille Y, Martinot B, Michel FB. Nasal challenge with pollen grains, skin-prick tests and specific IgE in patients with grass pollen allergy. Clin Allergy 1987;17:529-36.
13. Lack G, Nelson HS, Amran D, Oshiba A, Jung T, Bradley KL, et al. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma production in CD4+ T cells. J Allergy Clin Immunol 1997;99:530-8.
14. Alam R, Sim TC, Hilsmeier K, Grant JA. Development of a new technique for recovery of cytokines form inflammatory sites in situ. J Immunol Methods 1992;155:25-9.
15. Sim TC, Grant JA, Hilsmeier KA, Fukuda Y, Alam R. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 1994;149:339-44.
16. Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995;152:927-33.
17. Wang T, Brown MJ. MRNA quantification by real time TaqMan polymerase chain reaction: validation and comparison with RNase protection. Anal Biochem 1999;269:198-201.
18. Dreskin S, Dale S, Foster S, Martin D, Buchmeier A, Nelson H. Measurement of mRNA for IL-5 in scrapings of nasal epithelium from patients with allergic rhinitis undergoing nasal allergen challenge. J Immunol Methods 2002. In press.
19. Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001;87:501-5.
20. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames (IA): Iowa State University Press; 1980.
21. Conover WJ. Practical nonparametrics statistics. New York: Wiley; 1971.
22. Curran-Everett D. Multiple comparison: philosophies and illustrations. Am J Physiol Regulatory Integrative Comp Physiol 2000;279:R1-R8.
23. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valier S, Charlesworth MG, et al. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994;93:484-93.
24. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:439-46.
25. Des Roches A, Paradis L, Knani J, Hejjaoui A, Dhivert H, Chanez P, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3.
26. 1 correlates with clinical outcome. Clin Exp Allergy 1999;29:497-506.
27. Nakagawa T, Kozeki H, Katagirir J, Fujita Y, Yamashita N, Miyamoto T, et al. Changes of house dust mite-specific IgE, IgG and IgG subclass antibodies during immunotherapy in patients with perennial rhinitis. Int Arch Allergy Appl Immunol 1987;82:95-9.
28. Djurup R, Osterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass levels early in immune therapy. Allergy 1984;39:433-41.
29. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA- cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
30. Majori M, Caminati A, Corradi M, Brianti E, Scarpa S, Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000;30:341-7.